Cargando…

Comparative Biochemical Outcomes, Effectiveness and Tolerance of Densiron 68 and Oxane HD for the Management of Complicated Retinal Detachment

OBJECTIVES: To compare biochemical outcomes, effectiveness, and tolerance of two high-density silicone oils (HDSOs), silicone oil- RMN3 (Oxane(®) HD) and silicone oil-Densiron-68 (Densiron(®) 68), for the management of complicated retinal detachment (RD) associated with inferior proliferative vitreo...

Descripción completa

Detalles Bibliográficos
Autores principales: Keilani, Chafik, Augstburger, Edouard, Robin, Mathieu, Beaugrand, Amélie, Ores, Raphaëlle, Sahel, José-Alain, Ayello-Scheer, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961081/
https://www.ncbi.nlm.nih.gov/pubmed/31893589
http://dx.doi.org/10.4274/tjo.galenos.2019.24294
Descripción
Sumario:OBJECTIVES: To compare biochemical outcomes, effectiveness, and tolerance of two high-density silicone oils (HDSOs), silicone oil- RMN3 (Oxane(®) HD) and silicone oil-Densiron-68 (Densiron(®) 68), for the management of complicated retinal detachment (RD) associated with inferior proliferative vitreoretinopathy (PVR). MATERIALS AND METHODS: This was a retrospective, single-centre, comparative case series of 23 patients treated between September 2014 and June 2016. The main inclusion criteria were RD with inferior PVR receiving Oxane(®) HD or Densiron(®) 68 following pars plana vitrectomy. The main outcome measures were anatomical success, rate of RD recurrence, and best-corrected visual acuity (BCVA) at 6 months. Secondary outcomes were short-term complications. RESULTS: Twenty-three eyes were included: 16 eyes with Densiron(®) 68 tamponade and 7 eyes with Oxane(®) HD tamponade. Anatomical success under HDSO was significantly higher in the Densiron(®) 68 group (100%) than in the Oxane(®) HD group (42.8%) (p=0.0455). Recurrent RD was observed in 42.8% of eyes under Oxane(®) HD, but in none of the patients under Densiron(®) 68 (p=0.001). Six months after surgery, mean BVCA values (+/- standard deviation) with Densiron(®) 68 and Oxane(®) HD were 0.83±0.62 logMAR and 1.81±0.65 logMAR, respectively. BVCA was significantly better in the Densiron(®) 68 group (p=0.006). No significant differences were observed with regard to intraocular pressure, emulsification, or intraocular inflammation. CONCLUSION: Densiron(®) 68 appears to be more effective than Oxane(®) HD for the management of RD associated with PVR. A randomized, controlled, interventional study is needed to demonstrate this difference.